Fetal Tuberous Sclerosis: Sirolimus for the Treatment of Fetal rhabdomyoma

Fetal Pediatr Pathol. 2022 Oct;41(5):800-806. doi: 10.1080/15513815.2021.1948646. Epub 2021 Jul 19.

Abstract

Background: Sirolimus constitutes a safe and effective treatment for cardiac manifestations of tuberous sclerosis complex (TSC) in children but only four cases describing prenatal treatment of rhabdomyomas with mTOR inhibitors have been published.

Case: In this case, sirolimus was initiated at 26 weeks´ gestation in a pregnant woman with TSC with a fetus with a large rabdomyoma conditioning severe arrythmia. There was a significant reduction in the tumor size with ongoing treatment and a partial reversion of the arrythmia.

Conclusion: m-TOR inhibitors can be considered for severe cases of fetal rhabdomyomas with poor prognosis given its potencial benefits.

Keywords: Tuberous sclerosis; fetal therapy; rhabdomyoma; sirolimus.

MeSH terms

  • Arrhythmias, Cardiac
  • Child
  • Female
  • Fetus / pathology
  • Heart Neoplasms* / drug therapy
  • Heart Neoplasms* / pathology
  • Humans
  • Pregnancy
  • Rhabdomyoma* / drug therapy
  • Rhabdomyoma* / pathology
  • Sirolimus / therapeutic use
  • Tuberous Sclerosis* / complications
  • Tuberous Sclerosis* / drug therapy

Substances

  • Sirolimus